Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder
European Neuropsychopharmacology, Volume 3, No. 2, Year 1993
Notification
URL copied to clipboard!
Description
We have studied the effect of three fixed daily doses of fluoxetine in patients with obsessive-compulsive disorder (OCD) diagnosed according to DSM-III-R. Two hundred and fourteen patients were evaluated in an 8-week double blind, placebo-controlled study. A statistically significantly greater number of fluoxetine-treated patients achieved the prospectively defined criteria for clinical response when compared to placebo treatment. There was a statistically significant overall difference in the PGI rating of symptom change (P = 0.045) and a marginally significant difference (P = 0.089) in the CGI severity rating between groups. Pairwise comparison against placebo showed a marginally statistically significantly greater improvement (P = 0.059) in Y-BOCS-Total score for patients receiving fluoxetine 60 mg daily, and a significantly higher response rate in patients receiving fluoxetine 40 mg or 60 mg daily (P<0.05). One hundred and sixty one patients continued to a 16-week extension evaluation. There was no significant difference in the rate of reporting of any individual adverse event between placebo and fluoxetine, and the rate of discontinuation due to adverse events was low (< 6% in each study phase). This study supports the growing evidence for the safety and efficacy of fluoxetine in the treatment of OCD. © 1993.
Authors & Co-Authors
Montgomery, Stuart A.
United Kingdom, London
St Mary's Hospital
McIntyre, A.
South Africa, Tygerberg
Tygerberg Hospital
Osterheider, M.
Germany, Wurzburg
Universitätsklinikum Würzburg
Sarteschi, P.
Italy, Pisa
Università Di Pisa
Zitterl, W.
Austria, Vienna
Medizinische Universität Wien
Zohar, Joseph
Israel, Beer-sheva
Beer Sheva Mental Health Center
Birkett, Martin
United States, Indianapolis
Eli Lilly and Company
Wood, A. J.
United States, Indianapolis
Eli Lilly and Company
Statistics
Citations: 141
Authors: 8
Affiliations: 7
Identifiers
Doi:
10.1016/0924-977X(93)90266-O
ISSN:
0924977X
Research Areas
Disability